Get the Stockscreener App
6.80
1.49%
0.10
Pre-market:
6.80
Neuraxis Inc stock is traded at $6.80, with a volume of 81,115.
It is up +1.49% in the last 24 hours and down -13.60% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$6.70
Open:
$6.83
24h Volume:
81,115
Relative Volume:
0.44
Market Cap:
$84.21M
Revenue:
$4.28M
Net Income/Loss:
$-7.28M
P/E Ratio:
-8.3477
EPS:
-0.8146
Net Cash Flow:
$-6.17M
1W Performance:
+1.95%
1M Performance:
-13.60%
6M Performance:
+156.60%
1Y Performance:
+196.94%
1-Day Range:
$6.49
$6.995
1-Week Range:
$6.38
$7.064
52-Week Range:
$2.1963
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
6.80 | 84.21M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc Stock (NRXS) Latest News
NeurAxis Stockholders Approve Directors and Equity Compensation Plans - TipRanks
Neuraxis elects board members and approves plan amendments at annual meeting - Investing.com
NRXS Q1 2026 Earnings: Smaller-than-Expected Loss Bolsters Investor SentimentShare Repurchase Impact - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates Amid Ongoing Development FocusGuidance Accuracy Score - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates but Stock Declines on Broader ConcernsBalance Sheet Strength - newsline.com
NRXS Q1 2026 Earnings: EPS Beat Surprises as Pre-Revenue Biotech Tightens LossesEstimate Revision Count - The Legal Advocate
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionForward EPS Estimate - thelegaladvocate.com
Neuraxis Inc. (NRXS) Slides 2.15% as Key Support Level TestedPCR Divergence - The Legal Advocate
NRXS: Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets - TradingView
NRXS Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceRevenue Warning Signal - The Legal Advocate
Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Surpasses Estimates Amid Operational ProgressGAAP Earnings Report - The Legal Advocate
Neuraxis Inc. (NRXS) Holds Near Support After Marginal DeclineMA Cross Alert - Newser
Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Slips on Pre‑Revenue Concerns - Newser
NeurAxis Earnings Call Highlights Growth and Hurdles - TipRanks
NeurAxis (NRXS) Gains on Reimbursement Updates and Guideline MomentumShare Dilution Risk - The Legal Advocate
Minot Light Capital Fund Drops 2.7 Percent Amid Sector Rotation - HarianBasis.co
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum - Insider Monkey
Neuraxis (NRXS) Stock Analysis: -5.84% Loss — Key Levels 2026-05-18Stock Idea Hub - Newser
NeurAxis slides 21%, raises $5M via stock - MSN
The surprise hidden in Neuraxis NRXS last earnings report Q4 2025 Earnings Beat EstimatesCrowd Verified Signals - Newser
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y - Yahoo Finance
NeurAxis revenues up 80% to USD 1.6M in Q1 2026 - Medical Buyer
TradingKey - TradingKey
NeurAxis signals burn rate of $1M or less for rest of 2026 while targeting ~ $15M revenue for cash flow breakeven - MSN
Neuraxis Inc (NRXS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Coverage Challenges - Investing.com Canada
Earnings call transcript: Neuraxis Q1 2026 sees record revenue growth - Investing.com
Earnings call transcript: Neuraxis Q1 2026 sees record revenue growth By Investing.com - Investing.com India
Neuraxis Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
NRXS: Q1 2026 revenue up 80% year-over-year, with margin and adoption gains in covered markets - TradingView
NeurAxis, Inc. Reports 80% Revenue Growth in Q1 2026 Driven by CPT Code Assignment and Expanded Product Adoption - Quiver Quantitative
Neuraxis, INC 1Q 2026: Revenue $1.61M, EPS $(0.18) — 10-Q Summary - TradingView
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth - GlobeNewswire
NeurAxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
The surprise hidden in Neuraxis (NRXS) last earnings report | Q4 2025: Earnings Beat EstimatesCommunity Risk Signals - newser.com
Neuraxis | ARS: Annual Report to Security Holders - Moomoo
NeurAxis (NRXS) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
What the smart money sees in Neuraxis (NRXS) that retail does not (Near Lows) 2026-05-08Open Stock Picks - newser.com
Number of shareholders of Neuraxis, Inc. – AMEX:NRXS - TradingView
NRXS Neuraxis Q4 loss narrows more than expected, but shares dip 0.11% despite EPS beat.CFO Commentary - newser.com
The critical factors shaping Neuraxis (NRXS) future (Technical Weakness) 2026-05-08Retail Trader Ideas - newser.com
This Small-Cap Healthcare Stock Is Up 300% in a Year and Is Quickly Gaining a Following - inkl
NeurAxis will post first-quarter results before market open May 12 - Stock Titan
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 - GlobeNewswire
The Zacks Analyst Blog Highlights Alphabet, Walmart, Micron Technology and NeurAxis - Yahoo Finance
Top stock reports for Alphabet, Walmart & Micron - MSN
Bigger Capital, Michael Bigger report NRXS holdings (NRXS) and warrant limits - Stock Titan
Neuraxis | SCHEDULE 13G/A: Others - Moomoo
Neuraxis (NRXS) director Gil reports stock awards from Series B dividend - Stock Titan
Neuraxis | 4: Statement of changes in beneficial ownership of securities-Director Aharon Gil - Moomoo
Neuraxis Inc Stock (NRXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Cap:
|
Volume (24h):